Multinational pharmaceutical companies tend to stop domestic supply of essential drugs in a bid to raise their prices.Industry watchers said on Jan. 23 that Japanese multinational pharmaceutical company Kyowa Hakko Kirin Korea recently notified the Ministry of Food and Drug Safety (MFDS) that it wil
Samsung Bioepis' Imraldi, a biosimilar to Humira, gained 62 percent of the market in Germany as of Nov. 13, according to a tally released by medical market researcher IQVIA on Dec. 10. The figure was reached less than a month after the South Korean drug company launched Imraldi in Europe on Oct.
Chong Kun Dang Pharmaceutical Corp. (CKD) announced on Dec. 2 that it has recently received sales approval for its second-generation anemia biosimilar ”CKD-11101" from the Ministry of Food and Drug Safety of South Korea. CKD-11101 is the first biosimilar version of novel erythropoiesis stimulating p
As the global biosimilar market keeps growing, Korean pharmaceutical companies that have been focusing on traditional drugs are turning their attention to biosimilars. Unlike the newly established large biosimilar companies, these companies follow a strategy to target Japan, which is a niche market,
Dong-A ST announced on October 1 that Japanese chemical research institute SKK filed with the Japanese Ministry of Health, Labor and Welfare for permission to manufacture and sell DA-3880, a biosimilar for the treatment of anemia, whose production technology was transferred from Dong-A ST.DA-3880 is
South Korea’s food making conglomerate Daesang Corp. announced on October 16 that its business unit (President Chung Hong-un) has successfully developed L-Histidine, a high value added amino acid, for the first time in the country.L-Histidine is rich in red-flesh fish and external blue colored fish.
The number of approvals given to South Korean biosimilar clinical trials has surpassed that of multinational pharmaceutical companies.13 (in 10 items) out of the 25 biosimilar clinical trials (in 22 items) currently in progress are conducted by domestic companies. The number of approvals given clini